BUZZ-Sangamo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises after FDA clears application to start trial for pain treatment** Shares of genomic medicine company Sangamo Therapeutics SGMO.O rise 12.24% to $2.20 premarket
** Co says U.S. Food and Drug Administration has cleared co's application to start human trial for ST-503
** SGMO plans to initiate enrollment of patients in the early-to-mid stage study for ST-503 in mid-2025
** The therapy ST-503 is being studied for the treatment of intractable pain due to idiopathic small fiber neuropathy (iSFN), a type of chronic nerve pain
** Up to last close, stock had more than tripled YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments